Discovery

10-OH-HHC: The New HHC?

10-OH-HHC: The new HHC

The world of cannabinoids is constantly evolving, with the emergence of new derivatives that are pushing back the frontiers of scientific research and therapeutic applications. At the heart of this innovation is 10-OH-HHC, a recent derivative of HHC. This compound, formed by the oxidation of HHC, offers new prospects, both pharmacologically and therapeutically. This article aims to provide an in-depth understanding of 10-OH-HHC, exploring its chemical structure, pharmacological effects, metabolism and potential applications.

What is 10-OH-HHC?

10-OH-HHC, an oxidation product of hexahydrocannabinol (HHC), is not a typical cannabinoid, but rather a metabolite created by the liver. This process is triggered when HHC, itself obtained by the hydrogenation of THC (the main psychoactive constituent of cannabis), is exposed to the action of a liver enzyme, cytochrome P450. The action of this enzyme adds a hydroxyl group (-OH) to the tenth position of HHC, transforming its chemical structure to form 10-OH-HHC. This transformed molecule appears as a yellow, syrupy, honey-like liquid. Initial studies indicate that this structure may enable 10-OH-HHC to interact uniquely with the CB1 and CB2 cannabinoid receptors, modulating various biological processes.

When was 10-OH-HHC discovered?

The identification of 10-OH-HHC, also known as 10 hydroxy Hexahydrocannabinol, dates back to 1980, thanks to the team led by Raphaél Méchouam at the Israel Institute for Biological Research. At the time, they found that the compound had noticeable psychoactive effects at doses of 0.5 mg/kg and above. Despite this discovery, no further studies were carried out on this rather unusual molecule.

It wasn't until 2015 that 10-OH-HHC was fully isolated by a team of researchers at the University of Mississippi, led by Professor A. Ahmed. This study focused on the antimicrobial properties of hydrogenated HHC derivatives, such as 10-OH-HHC.

This cannabinoid, which in reality isn't really a cannabinoid, passed under the radar of all the laboratories specializing in the creation of semi-synthetic cannabinoids until March 2023, when large-scale production began in the USA with a view to exploiting its psychoactive effects and supplying countries such as Japan, where THC laws are very strict.

In France, it's still unknown to the general public, but not for much longer... Following the ANSM's ban on many semi-synthetic cannabinoids (THCP, HHCPO, THCJD etc.), laboratories have started to take an interest in it, and 10-OH-HHC is poised to become the great replacement for all these banned molecules. But for how long? Only time will tell...

Effects of 10-OH-HHC

The pharmacological effects of 10-OH-HHC are still under investigation, but early research suggests that it possesses cannabimimetic properties similar to those of THC. These effects include an influence on pain perception, appetite and mood. However, 10-OH-HHC may also offer unique benefits due to its distinct chemical structure. For example, preliminary studies show that it may have a different affinity for cannabinoid receptors, which could translate into specific therapeutic effects. In addition, 10-OH-HHC may be better tolerated and have fewer side effects than other, better-known cannabinoids.

  • Improved mood: Users often experience a marked improvement in their mood, accompanied by a feeling of euphoria and well-being.
  • Deep relaxation: 10-OH-HHC induces intense relaxation, without the sometimes abrupt effects of other cannabinoids.
  • Creativity boost: This compound has been shown to stimulate creativity, making tasks requiring imagination or brainstorming easier.
  • Physical relief: Its inhalable form provides rapid pain relief, ideal for those seeking immediate relief.
  • Increased appetite: Like many cannabinoids, it causes a sudden increase in appetite.
  • Sleep-enhancing: many report an ease of falling asleep once the effects have worn off, which can help insomnia sufferers.

The bioavailability of 10-OH-HHC is a crucial factor in determining its clinical efficacy. Bioavailability refers to the proportion of the substance that reaches the bloodstream and is able to exert its effect. 10-OH-HHC, like many cannabinoids, undergoes first-pass metabolism when ingested orally, meaning that a significant proportion of the compound is degraded before reaching the systemic circulation. This metabolism often leads to the formation of 10-carboxy-HHC, an inactive form of the compound. Alternative administration methods, such as vaporization or sublingual administration, can partially bypass this first-pass metabolism, allowing more direct absorption and potentially greater efficacy.

Applications and future prospects

The therapeutic potential of 10-OH-HHC is vast and merits further exploration. Possible applications include the treatment of chronic pain, anxiety disorders, sleep disorders, and certain neurodegenerative diseases. Due to its unique structure and potential interactions with the endocannabinoid system, 10-OH-HHC could offer innovative therapeutic options with tolerability and efficacy profiles different from those of currently used cannabinoids. Rigorous clinical trials will be needed to assess the safety, efficacy and best administration practices of this compound. In addition, the development of specific formulations, such as capsules, oils and topical products, could maximize the therapeutic benefits of 10-OH-HHC.

10-OH-HHC & MCP Boost? formula

10-OH-HHC is one of the main compounds in our MCP Boost formula. This blend (MCP Boost) is considered to be the most potent set of molecules currently available on the market. If you'd like to know more about MCP Boost and why the presence of 10-OH-HHC is essential, please read our article "What is MCP Boost?What is the MCP formula?"

Leave a comment

Your e-mail address will not be published. Required fields are marked with *.